Prestige Consumer Healthcare Inc. (PBH)
| Market Cap | 2.49B -24.6% |
| Revenue (ttm) | 1.10B -1.4% |
| Net Income | 172.01M -19.2% |
| EPS | 3.58 -16.1% |
| Shares Out | 47.37M |
| PE Ratio | 14.68 |
| Forward PE | 11.18 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 299,806 |
| Open | 51.50 |
| Previous Close | 51.21 |
| Day's Range | 51.22 - 52.54 |
| 52-Week Range | 42.62 - 71.07 |
| Beta | 0.33 |
| Analysts | Buy |
| Price Target | 67.80 (+29.22%) |
| Earnings Date | Aug 6, 2026 |
About PBH
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over the counter (OTC) health and personal care products in North America, Australia, and internationally. It operates in two segments, North American OTC Healthcare and International OTC Healthcare. The company offers analgesic powders under the BC and Goody's brand; various diaper rash treatments and skin protectants for babies under the Boudreaux's Butt Paste brand name; sprays and lozenges to relieve sore throats and mo... [Read more]
Financial Performance
In fiscal year 2026, PBH's revenue was $1.09 billion, a decrease of -4.31% compared to the previous year's $1.14 billion. Earnings were $190.30 million, a decrease of -11.32%.
Financial StatementsAnalyst Summary
According to 7 analysts, the average rating for PBH stock is "Buy." The 12-month stock price target is $67.8, which is an increase of 29.22% from the latest price.
News
Prestige Consumer Healthcare Transcript: Canaccord Genuity's 46th Annual Growth Conference
A consistent three-pillar strategy drives growth through brand investment, disciplined M&A, and strong financial management. Recent acquisitions (Breathe Right, LaCorium) are expected to accelerate international expansion and free cash flow, while innovation and e-commerce fuel organic growth.
Prestige Consumer Healthcare Earnings Call Transcript: Q1 2027
Q1 revenue grew 6.5% year-over-year, driven by strong GI and skincare brands, and two acquisitions are expected to add over 20% to annualized revenue. Adjusted EPS and free cash flow reached record levels, with updated guidance reflecting acquisition contributions and continued organic growth.
Prestige Consumer Healthcare Earnings release: Q1 2027
Prestige Consumer Healthcare released its Q1 2027 earnings on August 6, 2026, summarizing the period's financial results.
Prestige Consumer Healthcare Quarterly report: Q1 2027
Prestige Consumer Healthcare has published its Q1 2027 quarterly earnings report on August 6, 2026.
Prestige Consumer Healthcare Slides: Q1 2027
Prestige Consumer Healthcare has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 6, 2026.
Prestige Consumer Healthcare Inc. Reports Fiscal 2027 First Quarter Results
TARRYTOWN, N.Y., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its first quarter fiscal 2027 ended June 30, 2026.
Prestige Consumer Healthcare Inc. Completes Acquisition of LaCorium Health, Prices $400 Million Senior Notes Offering, and Announces First Quarter Fiscal 2027 Earnings Results Date
TARRYTOWN, N.Y., July 06, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of LaCorium Health ...
Prestige Consumer Healthcare Inc. Announces Offering of $400 Million Senior Notes
TARRYTOWN, N.Y., June 30, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE: PBH) (the “Company”) announced today that its wholly-owned subsidiary, Prestige Brands, Inc. (“Prestige Bran...
Prestige Consumer Healthcare Proxy statement: Proxy filing
Prestige Consumer Healthcare filed a proxy statement on June 29, 2026, providing details for shareholder voting and corporate governance matters.
Prestige Consumer Healthcare Inc. (PBH) Clear Eyes® and Pillar5 Problems Drive Stock Lower, HBSS Investigating
SAN FRANCISCO, June 25, 2026 /PRNewswire/ -- Investors in Prestige Consumer Healthcare (NYSE: PBH) saw the price of their shares fall over 11% on May 14, 2026 after the company revealed significant re...
Prestige Consumer Healthcare Inc Completes Acquisition of Breathe Right®
TARRYTOWN, N.Y., June 15, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of the Breathe Righ...
Prestige Consumer Healthcare Transcript: Oppenheimer 26th Annual Consumer Growth and E-Commerce Conference
The session highlighted a disciplined strategy focused on brand leadership, stable growth, and capital allocation, with recent major acquisitions (Breathe Right, LaCorium Health) expected to drive above-average growth. Consumer shifts favor mass and e-commerce, while operational improvements and international expansion underpin a positive outlook.
Prestige Consumer Healthcare Inc. to Participate in the Oppenheimer Annual Consumer Growth and E-Commerce Conference
TARRYTOWN, N.Y., June 05, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will participate in a fireside chat at the Oppenheimer 26th Annual Consumer Grow...
Prestige Consumer price target lowered to $72 from $86 at Canaccord
Canaccord lowered the firm’s price target on Prestige Consumer (PBH) to $72 from $86 and keeps a Buy rating on the shares. The firm updated its model following its Q4…
Prestige Consumer falls -14.0%
Prestige Consumer (PBH) is down -14.0%, or -$7.25 to $44.56.
Oppenheimer downgrades Prestige Consumer following weaker results, guidance
As previously reported, Oppenheimer analyst Rupesh Parikh downgraded Prestige Consumer (PBH) to Perform from Outperform following the company’s softer than expected Q4 results and weaker initial FY26 ...
Prestige Consumer Healthcare Earnings Call Transcript: Q4 2026
Fiscal 2026 saw a 4% revenue decline due to eye care supply issues and global disruptions, but GI and women's health brands performed well. Fiscal 2027 guidance anticipates 1%-3% organic growth, stable margins, and strong free cash flow, with pending acquisitions expected to drive future growth.
Prestige Consumer Healthcare Earnings release: Q4 2026
Prestige Consumer Healthcare released its Q4 2026 earnings on May 14, 2026, summarizing the period's financial results.
Prestige Consumer Healthcare Slides: Q4 2026
Prestige Consumer Healthcare has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on May 14, 2026.
Prestige Consumer Healthcare Annual report: Q4 2026
Prestige Consumer Healthcare has published its Q4 2026 annual report on May 14, 2026.
Prestige Consumer downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded Prestige Consumer (PBH) to Perform from Outperform.
Prestige Consumer Healthcare Inc. Reports Fiscal 2026 Results, Announces Acquisition of LaCorium Health
TARRYTOWN, N.Y., May 13, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today reported financial results for its fourth quarter and fiscal year ended March 31, 2026.
Prestige Consumer price target lowered to $65 from $77 at Oppenheimer
Oppenheimer analyst Rupesh Parikh lowered the firm’s price target on Prestige Consumer (PBH) to $65 from $77 and keeps an Outperform rating on the shares. The firm notes the company…
Prestige Consumer Healthcare to Release Fiscal 2026 Fourth Quarter and Year-End Earnings Results
TARRYTOWN, N.Y., April 30, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer Healthcare Inc. (NYSE:PBH) today announced that it will issue its fiscal 2026 fourth quarter and year-end earnings release on Wedn...
Prestige Consumer Healthcare to Buy Breathe Right, Other Brands for $1.045 Billion
Prestige signed a deal to buy a portfolio of brands that includes the Breathe Right nasal strip from privately held Foundation Consumer Healthcare.